Curis, Inc. (CRIS)

14,31 -0,21 (-1,45%) In data: 11:08AM EDT. Mercato aperto.

Curis, Inc.

Building C
Suite 500 128 Spring Street
Lexington, MA 02421
United States
617 503 6500
https://www.curis.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 49

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. James E. Dentzer	President, CEO, Secretary, Treasurer & Director	1,07M	N/D	1967
Ms. Diantha Duvall CPA, M.B.A.	CFO and Principal Financial & Accounting Officer	719,02k	N/D	1972
Dr. Jonathan B. Zung Ph.D.	Chief Development Officer	691,27k	N/D	1966
Mr. Mark W. Noel	Vice President of Technology Management & Intellectual Property	279,28k	85,7k	1959
Ms. Elif McDonald	VP of Investor Relations & Corporate Communications	N/D	N/D	N/D
Dr. Reinhard Wilhelm von Roemeling M.D.	Senior Vice President of Clinical Development	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Curis, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.